Clinical Trials Logo

Muscle Spasticity clinical trials

View clinical trials related to Muscle Spasticity.

Filter by:

NCT ID: NCT02020980 Completed - Clinical trials for Lower Limb Spasticity

RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke

RELIEF
Start date: April 2014
Phase:
Study type: Observational

The objective of this study is to demonstrate the effect of intramuscular BoNT-A injections in relieving pain, in a broad population of patients who suffer pain as the primary problem associated with spasticity. Thus, this study will help to expand the information that is available regarding the impact of BoNT-A treatment in routine clinical practice conditions. Treatment goals can vary greatly from one patient to another and there is no unique, single outcome that reflects the treatment benefits in all the cases. Therefore, this study with special focus on the achievement of therapeutic goals, will allow the identification of each patient's specific goals regarding the improvement of the functional outcomes, the quality of life and patient well-being.

NCT ID: NCT02002884 Completed - Cerebral Palsy Clinical Trials

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

XARA
Start date: March 28, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.

NCT ID: NCT01968902 Completed - Multiple Sclerosis Clinical Trials

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

Start date: November 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if Xeomin® will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.

NCT ID: NCT01964547 Completed - Multiple Sclerosis Clinical Trials

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Start date: January 2012
Phase: Phase 4
Study type: Interventional

A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period of 48 weeks. Secondary objectives were to evaluate the effect of Sativex on mood and spasticity and to assess the safety and tolerability of Sativex.

NCT ID: NCT01945684 Completed - Stroke Clinical Trials

A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity

Start date: September 2013
Phase: Phase 3
Study type: Interventional

Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger, elbow, thumb)Spasticity.

NCT ID: NCT01930786 Completed - Muscle Spasticity Clinical Trials

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

ASPIRE
Start date: October 16, 2013
Phase:
Study type: Observational

This is a registry study in adults with spasticity to determine onabotulinumtoxinA use in clinical practice. Treatment will be administered in accordance with physician standard practice. All treatment decisions lie with the physician.

NCT ID: NCT01915459 Completed - Stroke Clinical Trials

Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity

Start date: June 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients.

NCT ID: NCT01915342 Completed - Muscle Spasticity Clinical Trials

Developing Optimal Focal Muscle Vibration for Improving Spasticity

Start date: August 2013
Phase: N/A
Study type: Interventional

The overall aim of the proposed study is to determine optimal parameter of focal muscle vibration for improving spasticity and identify neurophysiological mechanism in healthy subjects. In investigation I-1, subjects will undergo focal muscle vibration with 40, 80, 120 Hz frequency at the medial gastrocnemius muscles (mGCM). As a surrogate maker of spasticity, H-reflex and compound motor action potential (CMAP) of the tibial nerve at mGCM will be recorded pre, during, and post vibration. In investigation I-2, subjects will undergo focal muscle vibration with 0.1, 0.3, 0.5 mm amplitude at mGCM. H-reflex and CMAP of the tibial nerve at mGCM will be recorded pre, during, and post vibration. In investigation II, subjects will undergo focal muscle vibration with predetermined parameters by the investigation I at mGCM. H-reflex and CMAP of the tibial nerve and motor evoked potential at mGCM will be recorded pre, during, and post vibration.

NCT ID: NCT01905683 Completed - Clinical trials for Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy

Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.

NCT ID: NCT01898520 Completed - Cerebral Palsy Clinical Trials

A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Start date: December 2013
Phase: Phase 3
Study type: Interventional

A study to assess the effects of Sativex treatment on spasticity in a population of children and adolescents aged from 8 to 18 years with cerebral palsy or traumatic central nervous system injury. Efficacy (ability to improve symptoms), safety and tolerability will be monitored.